HealthPharma & Biotech
Abzena PLC

Abzena CEO on the potential for acquisitions and reaching profitability

John Burt, the chief executive of Abzena (LON:ABZA), discusses the company’s business model, the busy period of newsflow ahead, and the potential for acquisitions.

While profitability may be a few years away yet, Burt says there are already a few products in the clinic that the company will be able to earn royalties from.

The company raised £20 million in last July’s IPO, which Burt says ‘gives a good platform for the future because our business model doesn’t require a lot of capital because we’re not funding clinical trials’.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Full interview: Alchemist sees big market in China for medical cannabis sales

Alchemist (CSE: AMS) CEO Paul Mann and Vice President of Business Development, Asia Pacific Johnson Lee joined Steve Darling from Proactive Vancouver to discuss Alchemist looking for opportunities for cannabis in the emerging cannabis market.  Mann and Lee talk about what the industry...

2 days, 4 hours ago

2 min read